Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients

Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 687 in its research report dated November 06, 2023.

Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 670 in its research report dated November 08, 2023.

Motilal Oswal recommended Neutral rating on Zydus LifeSciences with a target price of Rs 660 in its research report date November 07, 2023.

Zydus added that LiqMeds Group has capabilities and specialisation in development, manufacturing and supply of oral liquid products for global markets, which it currently commercializes through partners.

Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease in India.

Zydus Lifesciences on October 20 announced that the USFDA approved its New Drug Application (NDA) for ZITUVIOTM (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg, company said in its statement.

The Sugammadex injection will be manufactured at the group’s manufacturing facility near Vadodara in Gujarat

The recalls were reported in the daily U.S. Food and Drug Administration Recall Information updates

“We have received final approval from the USFDA for Clindamycin Phosphate Gel USP. Clindamycin is an antibiotic which works by stopping the growth of bacteria and helps to decrease the number of acne lesions," Zydus Lifesciences said in a regulatory filing at the exchanges.

Geojit is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 750 in its research report dated August 22, 2023.

The company is slated to be included in the Nifty Next 50 index on September 29 of the ongoing fiscal.

Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 650 in its research report dated August 12, 2023.

Nuvama downgrades Zydus to ‘hold’. It says Q1 results are unlikely to be repeated, as exclusivity of epilepsy drug Trokendi is declining and revenue from blood cancer drug Revlimid remains 'lumpy'

Revenue for the quarter came in at Rs 5,139.6crore, 29.6 percent higher than Rs 3,964.3 crore in the same quarter of the previous fiscal, the company said in an exchange filing.

Zydus Lifesciences has received final approval from the USFDA to manufacture and market Indomethacin suppositories

The plerixafor injection, used by patients with certain types of cancer to prepare them for a stem cell transplant, will be manufactured at the group’s facility in Ahmedabad

Net Sales are expected to increase by 24 percent Y-o-Y (up 0.8 percent Q-o-Q) to Rs 5,050.3 crore, according to Nirmal Bang.

The company has also received final approval from the United States Food and Drug Administration for Oxcarbazepine tablets. Oxcarbazepine is used to treat epilepsy

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 663 in its research report dated June 28, 2023.

The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad.

Analysts predict the partial acquisition is a stepping stone for the company to venture into the diagnostic space at a later stage.

The proposed investment in Mylab will help the company to participate in growing diagnostics space which is expected to witness increased penetration through in-clinic solutions with Point of Care Testing devices, said Zydus Lifesciences.